Mignar, Miglitol

Mignar is used in the treatment of type 2 diabetes mellitus which is also known as non-insulin-dependent diabetes (NIDDM).

Mignar functions to stop the occurrence of PPHG (postprandial hyperglycemia), which is also known as high blood sugar after food consumption. The active ingredient in Mignar is a an oral alpha glucosidase inhibitor derived from desoxynojirimycin. When administered orally, Mignar causes a reduction in the amount of sugar absorbed into the blood after you eat a meal. However, Mignar's effect is not due to stimulating the release of insulin. Instead, carbohydrates are prevented from being digested into monosaccharides (a form of sugar that can be easily absorbed into the blood), thereby preventing a rise in blood sugar after eating.

Patients who take Mignar may suffer from such side effects;

Gas,
Pain occurring in the stomach,
Passing stools which are loose,
Mild symptoms affecting the skin,
Gastrointestinal reactions causing pain,
Skin rash,
Flatulence,
Abdominal pain,
Diarrhoea